Navigation Links
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Date:2/9/2016

SAN FRANCISCO, February 9, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it will be a featured presenting company at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference which takes place on February 10-11, 2016 in New York City. The Company's presentation will be given on Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA. Amarantus' CEO will be available for one-on-one meetings at the conference.

About Amarantus BioScience Holdings, Inc. 

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard) that led to MANF's discovery.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statements 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com


'/>"/>
SOURCE Amarantus Bioscience Holdings, Inc
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
2. Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
3. Amarantus to Present at ICV Sonoma Event
4. Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
5. Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
6. Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
7. Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinsons Disease Levodopa-induced Dyskinesia (PD-LID)
8. Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
9. Aethlon Medical to Present at Source Capital Groups 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
10. Cryoport to Present at the Source Capital Groups 2016 Disruptive Growth & Healthcare Conference
11. Delcath Systems to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... Abilene Christian University (ACU) is offering ... (DNP) degree. The online BSN to DNP program pathway is meant to serve as ... in Nursing (BSN) degree to a Doctor of Nursing Practice degree. , Traditionally, ...
(Date:9/11/2019)... ... September 11, 2019 , ... This event is free and takes place on ... noon to 4 p.m. The Foundation for Senior Services Wellness Expo will feature entertainment ... with experts in a variety of fields. , The mission of the Foundation ...
(Date:9/11/2019)... ... ... HOLLOWAY AMERICA, a leading manufacturer of stainless steel vessels and ... it will showcase its problem-solving vessels and tanks at several shows this fall from ... be at ISPE San Diego’s 27th Life Science Resource Fair at the Del Mar ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... 2019 , ... Women’s Excellence is excited to announce the opening of their ... Suite 103, Royal Oak, MI 48073 in the heart of Royal Oak off Woodward ... services in a contemporary, spa-like atmosphere. We are thrilled to be in a ...
(Date:9/11/2019)... ... September 10, 2019 , ... Episcopal Relief & ... vulnerable communities impacted by Hurricane Dorian. , In partnership with the Episcopal ... of Georgia, and the Episcopal Farmworker Ministry, Episcopal Relief & Development is giving ...
(Date:9/9/2019)... ... September 09, 2019 , ... Sharon, the respected Practice Administrator ... of Dental Office Management (AADOM) Annual Conference. This year, esteemed dentist, Dr. Patrick ... is Sharon’s third nomination in a row. The entire team at Cieplak Dental ...
(Date:9/9/2019)... NEW YORK (PRWEB) , ... ... ... Center of NYC ( https://www.orthodonticscenternyc.com ) located on the Upper East Side ... division to their busy orthodontic practice. The pediatric orthodontic division specializes in ...
(Date:9/8/2019)... ... , ... The reviews from patients of ABM Medical Clinic who have had ... pain free fat loss system, has patients booking their sessions and recommending this procedure ... state of the art technology incorporating radio frequency and heat to rid the fat ...
Breaking Medicine News(10 mins):